Keppra, Robaxin, and Lyrica: Effects on Insulin and Glucose
None of these three medications—Keppra (levetiracetam), Robaxin (methocarbamol), or Lyrica (pregabalin)—are listed among medications that significantly affect glucose metabolism or require diabetes screening according to current ADA guidelines, though Lyrica carries specific considerations for diabetic patients.
Keppra (Levetiracetam)
Levetiracetam does NOT affect insulin secretion or glucose levels. The FDA label confirms that levetiracetam is not metabolized by liver cytochrome P450 enzymes and has no significant protein binding 1. The drug's pharmacokinetic profile shows no interaction with hypoglycemic agents including glyburide, insulin, or metformin 2.
- Metabolism: Enzymatic hydrolysis independent of liver enzymes—no effect on glucose-regulating pathways
- Drug interactions: Population pharmacokinetic studies specifically demonstrate no effect on or from hypoglycemic medications 2
- Clinical evidence: Recent research actually suggests levetiracetam may have protective effects in diabetic models by suppressing neuroinflammation, without affecting glucose metabolism 3
Key point: Unlike valproate (which causes insulin resistance), levetiracetam shows a better metabolic safety profile with no insulin resistance or metabolic dysfunction after 6 months of therapy 4.
Robaxin (Methocarbamol)
Methocarbamol has no documented effects on insulin or glucose metabolism. This muscle relaxant is not mentioned in any diabetes management guidelines 5, 6, 7 and does not appear in lists of medications requiring glucose monitoring.
- No evidence in the literature of glucose or insulin effects
- Not included in ADA screening recommendations for medications that increase diabetes risk 5
Lyrica (Pregabalin)
Pregabalin does NOT directly affect insulin secretion or glucose control, but requires monitoring in diabetic patients due to weight gain and rare hypoglycemia risk.
Effects in Diabetic Patients
The FDA label explicitly states: "LYRICA treatment did not appear to be associated with loss of glycemic control (as measured by HbA1C)" 2. A dedicated study of pregabalin in painful diabetic neuropathy found no clinically meaningful effects on HbA1c or glucose levels 8.
Important Caveats for Diabetics
Weight gain is the primary metabolic concern:
- Diabetic patients on pregabalin gained an average of 1.6 kg (range: -16 to 16 kg) 2
- In a 2-year cohort, average weight gain was 5.2 kg 2
- Weight gain can occur with or without edema
- Caution when combining with thiazolidinediones: 7.5% of patients on both drugs experienced weight gain vs 4% on pregabalin alone 2
Rare hypoglycemia risk in specific populations:
- Japanese database analysis identified pregabalin-associated hypoglycemia (reporting odds ratio 2.25) 9
- Highest risk: Age ≥70 years (OR 2.76) and weight <40 kg (OR 2.97) 9
- This occurred in patients NOT taking antidiabetic agents 9
- Mechanism unclear but clinically relevant in elderly, low-weight patients
Drug Interactions
Pregabalin has no pharmacokinetic interactions with diabetes medications:
- No effect on glyburide, insulin, or metformin 2
- Not metabolized by cytochrome P450 enzymes 2
- Does not affect glucuronidation pathways 2
Clinical Recommendations
For patients with diabetes:
- Keppra: Use without glucose-related concerns—no monitoring needed
- Robaxin: Use without glucose-related concerns—no monitoring needed
- Lyrica:
- Monitor weight regularly (primary concern)
- In elderly patients (≥70 years) with low body weight (<40 kg): Be aware of rare hypoglycemia risk and consider glucose monitoring during initiation 9
- Check HbA1c at baseline and periodically, though direct effects are unlikely 2
- Avoid combining with thiazolidinediones when possible due to additive weight gain 2
None of these medications are included in the ADA's list of drugs requiring diabetes screening (which includes glucocorticoids, statins, PCSK9 inhibitors, thiazide diuretics, HIV medications, and second-generation antipsychotics) 5.